||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Valirx Share Discussion Threads
Showing 18326 to 18349 of 18350 messages
|Odd position that we are in. Can't really comment on the commercial position of 401, as all we know is that it's not labotomizimg anyone. Which is good. It's super Valium Afterall, do this was a genuine concern.On 201 I estimate we have a 75% chance of passing full phase 2. There is on average s 50% pass rate on phase 3, and 80% pass rate on phase 4. So at present I make that a 30% chance if an eventual £1bn revenue per year. You can DCF model that to death, but if those facts I think we are pretty certain. Competing approved treatments involve castration, so the 201 product proposition appears sound.A £4m mcap. Go figure :(|
|Wake me up before you go go has the song goes...
also a very poor trading week after the update we had...|
|Yes he really isHe will ramp and beg strangers to buy like some desperate foolHe probably holds 200 shares lol|
|Patv...Yes like a cur with his tail between his legs!What a plonker!
|Pat January is a bad time for Sean !
He will be back with his usual vitriol
thebossman this will be spun pit as long as there is a wage to draw
I suspect this will get very near previous lows before that happens though
.3 of a penny
|Yoda poor guy disappeared as couldn't ramp|
|Caut.so you are saying that valirx is going down the pan then.....|
|don't start crying when all is lost here lol
14 Dec '16 - 21:25 - 5079 of 5140
PLEASE SIGN THIS.
Aim comapanies need investigating.
because NOTHING will be done about it ! ! ! ! ! !|
|is this the lull before the storm
when the next placing is announced
|7Dig trading statement 17/01/17
WHAT THE MARKET HAS COMPLETELY MISSED.
HI RES AUDIO : MQA
MQA the new Worldwide Hi Res listening format for streaming music.
Sony,Universal,Warner catalogs converted by spring 2017.
7Digital B2B licensing and streaming partnership with MQA is currently valued at ZERO
7Dig market cap today of £10M and turned profitable in last Quarter.
The music labels now have yet another stranglehold on the likes of Spotify in that they will not be given access to HI RES music if the labels want to run every show in town themselves.
7Dig hold a pack full of cards and yet the Square Mile, those that should be on the ball have not seen it in front of their very eyes.👀
Both these articles came out of CES 2017 held in Las Vegas last week. (January 2017)
7 Dig last week in a print interview (not an RNS)
"Downton said that 7digital is working on a number of launches of high-res streaming services in 2017 for clients, and that these services will go beyond pure audio quality."
MQA have just said this at CES held in Las Vegas last week (January 2017)
Before the year is out, four to five services could be streaming high-res, said MQA chairman Bob Stuart. Stuart"s company developed Master Quality Authenticated (MQA) technology to reduce bandwidth requirements to make it practical to stream master-quality audio.
At some stage in the next few months the three massive music labels Sony, Universal, and Warner will officially announce their own Hi Res Music Streaming offerings.
That in itself could be the end of Spotify, and the other subscription streaming music services that currently offer a very poor listening experience due to the age old file storage capacity issue on mobile devices. (This is not a constraint with MQA.)
They will not be handing over to outsiders the new content platform that artists and listeners will demand going forward.
7Digital announced yesterday in the trading statement they are now working with all three record labels.|
|Anyone following Glen Arnold's ADVFN newsletter ?
His focus is primarily on Deep Value shares. I notice I already hold or have held most of the shares he covers.
The newsletter is subscription only. However for just £59 per year, i'd say it is well worth following.
The Arnold Investment Fund
For the past five years my main investment focus has been outside of the equity market, as I concentrated on buying houses and gaining planning permission for one thing or another. This worked out well, but in 2013, after resigning my Chair, I became a lot more serious about share investing. I created the Arnold Investment Fund. This is purely a personal fund, not open to other investors.
The fund is split into a number of different sub-portfolios:
• Extraordinarily strong franchise investing.
These have such a strong economic franchise and such a deep and dangerous moat to keep out would-be rivals that they are likely to be generating high returns for shareholders many years from now. Very occasionally, the market gets too pessimistic about the prospects of some of these companies and pushes share prices into bargain territory.
• Net current asset value investing
Buy shares at a price below the net current asset value. NCAV is balance sheet current assets minus all the liabilities (both short- and long-term). Long term assets are generally to be counted at zero value. NCAV investing also requires a qualitative assessment filter of (a) financial strength, (b) managerial quality (competence and integrity) and (c) earnings power over the long run (links to strategic evaluation).
• Return reversal with Piotroski factors.
There is evidence showing that the purchase of a portfolio of those shares exhibiting appalling returns over the past five years then go on to out-perform the market by a significant margin. Returns on these ‘loser portfolios’ can be further enhanced by applying the accounting ratio analysis proposed by Piotroski in his 2000 paper, and few other elements.
• Value filter with Piotroski filter.
The evidence showing the out-performance of properly-constructed value portfolios relative to the market and to the glamour portfolios is very strong. This has been shown in many time periods, many countries and using various statistical tests. I apply the best ideas in this field to select a robust portfolio and then enhance it further by using a Piotroski-type filter.
• High growth companies at good prices.
This is the most difficult approach of all. I expect to find few companies that I know enough about to, with confidence, buy their shares. Through scuttlebutt and other means I need to satisfy myself that the current high PER is justified by the extraordinary qualities of the technical, sales and managerial teams. They must have such a strong competitive advantage that they can produce a string of extraordinary products/services which the competition cannot touch; and they can do this for decades ahead, not just the next year or two. This is following Philip Fisher’s approach (see FT Guide to Value Investing or Great Investors). I’m not at all optimistic that I can get close to Fisher’s tenacity, knowledge and eye for detail, so I frequently have to accept that this type of investing is beyond my circle of competence.|
|True bossman Up 13 closed dwn 2k openI'm happy but got lots of warrants so want these to rocket|
|Pat. you have made a few bob so you have no complaints..|
|Prefer mtf to thisBetter mgmnt and more chance of being successfulAeg up today ..love em|
|17 January 2017 07:00
ASTRAZENECA EXPANDS 1ST-LINE LUNG CANCER
IMMUNO-ONCOLOGY PROGRAMME OPPORTUNITIES
Refined endpoints and statistical analysis plan in the Phase III MYSTIC trial..
First Patient Dosed in Phase II Breast Cancer Trial
Evgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, is pleased to announce that the first patient has been dosed in the Company's Phase II clinical trial of SFX-01 in breast cancer.
The STEM (SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer) trial is investigating SFX-01 in combination with different hormone-based therapies in 60 metastatic breast cancer patients whose cancer cells are estrogen-receptor positive (ER+). The primary objectives of the STEM trial are to evaluate safety and efficacy (via tumour imaging) in patients starting to become resistant to mainstream hormone therapy. Patients will be enrolled into one of three study arms (SFX-01 in combination with either aromatase inhibitors, tamoxifen or fulvestrant) based on their current therapy.|
|K9pI could put in substantially moreBut who cares as this is a pile of pooIn fact wouldn't surprise me if CM price target here is 4p too high!!|
|My investment was 7kEnd ofIf there wasn't a drawdown I would put 250k in but I don't rate this mgmnt so I wont|
|Your shares are only worth what you trade at. Those who hold are the small losers. The big buyers of stock from the company make much. And that is on every issue of stock. Shame about us small minority holders.|
|Pat..they are Directors to make money for themselves first of all...|
|All bod like their own sharesOtherwise they wouldn't be directors!! Lol|
|The bloody share price because GM said "it bloody works"but Ask him if he thinks the financing in place since sept 2016 has had a negative effect on valirx share price he has no answer to his shareholders from my enquires to him.....|
|What will it rocket bossman please explain|
|its gonna rocket soon..LoL so 3.5p no way pedro|
|How low can this go .in lookijg to enter around 3.5p if poss here think upside to downside potential makes it a good punt here .any thoughts from the negatives and positives all welcome with there views|